Almitrine: Difference between revisions

	WikiDoc Resources for Almitrine
Articles
Most recent articles on Almitrine Most cited articles on Almitrine Review articles on Almitrine Articles on Almitrine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Almitrine Images of Almitrine Photos of Almitrine Podcasts & MP3s on Almitrine Videos on Almitrine
Evidence Based Medicine
Cochrane Collaboration on Almitrine Bandolier on Almitrine TRIP on Almitrine
Clinical Trials
Ongoing Trials on Almitrine at Clinical Trials.gov Trial results on Almitrine Clinical Trials on Almitrine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Almitrine NICE Guidance on Almitrine NHS PRODIGY Guidance FDA on Almitrine CDC on Almitrine
Books
Books on Almitrine
News
Almitrine in the news Be alerted to news on Almitrine News trends on Almitrine
Commentary
Blogs on Almitrine
Definitions
Definitions of Almitrine
Patient Resources / Community
Patient resources on Almitrine Discussion groups on Almitrine Patient Handouts on Almitrine Directions to Hospitals Treating Almitrine Risk calculators and risk factors for Almitrine
Healthcare Provider Resources
Symptoms of Almitrine Causes & Risk Factors for Almitrine Diagnostic studies for Almitrine Treatment of Almitrine
Continuing Medical Education (CME)
CME Programs on Almitrine
International
Almitrine en Espanol Almitrine en Francais
Business
Almitrine in the Marketplace Patents on Almitrine
Experimental / Informatics
List of terms related to Almitrine

Almitrine
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	R07AB07 (WHO) ;
Identifiers
	IUPAC name 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-N,N'-; diprop-2-enyl-1,3,5-triazine-2,4-diamine;
CAS Number	27469-53-0 ;
PubChem CID	33887;
DrugBank	DB01430 ;
ChemSpider	31235 ;
UNII	9A1222NBG4;
KEGG	D07126 ;
ChEBI	CHEBI:53778 ;
ChEMBL	ChEMBL1183717 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C26H29F2N7
Molar mass	477.552 g/mol
3D model (JSmol)	Interactive image;
Melting point	181 °C (357.8 °F)
	SMILES Fc1ccc(cc1)C(c2ccc(F)cc2)N4CCN(c3nc(nc(n3)NC\C=C)NC\C=C)CC4;
	InChI InChI=1S/C26H29F2N7/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33) ; Key:OBDOVFRMEYHSQB-UHFFFAOYSA-N ;
(what is this?) (verify)

VisualWikitext

Latest revision as of 17:23, 18 August 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Almitrine (marketed as Duxil by Servier) is a diphenylmethylpiperazine derivative classified as a respiratory stimulant by the ATC. It enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep. A significant literature exists for this compound, including over 60 papers that Medline labels as reviews.

The clinical efficacy of almitrine-raubasine combination therapy for age related cerebral disorders and functional rehabilitation after stroke has been reviewed by Allain and Bentué-Ferrer.^[1] They summarize two studies in which almitrine-raubasine improved some symptoms significantly more than placebo, especially in vascular cases. Their paper also suggests that other studies have shown a beneficial effect of this compound on neurosensory vascular disorders, specifically chorioretinal dysfunctions (visual symptomatology) and vertigo associated with electronystagmographic modifications. This paper further claims that the dosage and tolerance of the compound have been confirmed in a French multi-center study of 5,361 outpatients.

References

↑ Allain, H.; Bentué-Ferrer, D. (1998). "Clinical Efficacy of Almitrine-Raubasine". European Neurology. 39 (Suppl. 1): 39–44. doi:10.1159/000052069. PMID 9516074.

[1] Allain, H.; Bentué-Ferrer, D. (1998). "Clinical Efficacy of Almitrine-Raubasine". European Neurology. 39 (Suppl. 1): 39–44. doi:10.1159/000052069. PMID 9516074.

[1]

@@ Line 4: / Line 4: @@
 | verifiedrevid = 477318381
 | IUPAC_name = 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-''N'',''N'''-<br>diprop-2-enyl-1,3,5-triazine-2,4-diamine
-| image = Almitrine structure.svg
+| image = Almitrine.png
 <!--Clinical data-->
@@ Line 57: / Line 57: @@
 | melting_point = 181
 }}
+              __NOTOC__
-'''Almitrine''' (marketed as '''Duxil''' by [[Servier]]) is a [[diphenylmethylpiperazine]] [[chemical derivative|derivative]] classified as a [[respiratory]] [[stimulant]] by the [[Anatomical Therapeutic Chemical Classification System|ATC]]. It enhances respiration by acting as an [[agonist]] of peripheral [[chemoreceptors]] located on the [[carotid bodies]]. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with [[chronic obstructive pulmonary disease]]. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep.
+{{SI}}
+{{CMG}}
+==Overview==
+'''Almitrine''' (marketed as '''Duxil''' by Servier) is a diphenylmethylpiperazine [[chemical derivative|derivative]] classified as a [[respiratory]] [[stimulant]] by the [[Anatomical Therapeutic Chemical Classification System|ATC]]. It enhances respiration by acting as an [[agonist]] of peripheral [[chemoreceptors]] located on the [[carotid bodies]]. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with [[chronic obstructive pulmonary disease]]. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep.
 A significant literature exists for this compound, including over 60 papers that Medline labels as reviews.
 The clinical efficacy of almitrine-raubasine combination therapy for age related cerebral disorders and functional rehabilitation after stroke has been reviewed by Allain and Bentué-Ferrer.<ref>{{cite journal |doi=10.1159/000052069 |title=Clinical Efficacy of Almitrine-Raubasine |year=1998 |last1=Allain |first1=H. |last2=Bentué-Ferrer |first2=D. |journal=European Neurology |volume=39 |issue=Suppl. 1 |pages=39–44 |pmid=9516074}}</ref> They summarize two studies in which almitrine-raubasine improved some symptoms significantly more than placebo, especially in vascular cases.  Their paper also suggests that other studies have shown a beneficial effect of this compound on neurosensory vascular disorders, specifically chorioretinal dysfunctions (visual symptomatology) and vertigo associated with electronystagmographic modifications.  This paper further claims that the dosage and tolerance of the compound have been confirmed in a French multi-center study of 5,361 outpatients.
-== See also ==
-* [[Diphenylmethylpiperazine]]
-* [[Servier]]
 ==References==
-{{reflist}}
+{{reflist|2}}
-{{Respiratory stimulants}}
-{{Piperazines}}
 [[Category:Piperazines]]
@@ Line 77: / Line 77: @@
 [[Category:Respiratory agents]]
 [[Category:Organofluorides]]
+[[Category:Drug]]
-{{respiratory-system-drug-stub}}

Almitrine: Difference between revisions

Latest revision as of 17:23, 18 August 2015

Overview

References

Navigation menu

Search